Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study
Limited evidence suggests that isotretinoin may be associated with inflammatory bowel disease (IBD). To explore this association, we conducted a retrospective population-based cohort study in British Columbia, Canada, among participants who were newly treated with isotretinoin or topical acne medica...
Gespeichert in:
| Veröffentlicht in: | Journal of investigative dermatology 2013-04, Vol.133 (4), p.907-912 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 912 |
|---|---|
| container_issue | 4 |
| container_start_page | 907 |
| container_title | Journal of investigative dermatology |
| container_volume | 133 |
| creator | Alhusayen, Raed O. Juurlink, David N. Mamdani, Muhammad M. Morrow, Richard L. Shear, Neil H. Dormuth, Colin R. |
| description | Limited evidence suggests that isotretinoin may be associated with inflammatory bowel disease (IBD). To explore this association, we conducted a retrospective population-based cohort study in British Columbia, Canada, among participants who were newly treated with isotretinoin or topical acne medications. The entire population of untreated provincial residents aged 12–29 years served as the reference group. During the 12-year study period, we identified 46,922 participants treated with isotretinoin, 184,824 treated with a topical acne medication, and 1,526,946 untreated individuals. Compared with untreated individuals, we observed no significant association between isotretinoin use and IBD (rate ratio (RR) 1.14; 95% confidence interval (CI) 0.92–1.41). As expected, we found no association with topical acne medications (RR 1.11; 95% CI 0.99–1.24). In prespecified secondary analyses, isotretinoin was associated with IBD among individuals aged 12–19 years (RR 1.39; 95% CI 1.03–1.87) and topical acne medications were associated with ulcerative colitis (RR 1.19; 95% CI 1.00–1.42). Our primary analyses found no association between isotretinoin and IBD. In prespecified secondary analyses, some evidence was found of associations with isotretinoin as well as topical acne medications, suggesting a possible association between IBD and acne itself. Additional research is needed to explore this possibility. |
| doi_str_mv | 10.1038/jid.2012.387 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3728031</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022202X15361728</els_id><sourcerecordid>2916394071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-54a9f7d07ac2accadf3a59cc34e21dcec357a059a38ef15de62d130a172cf1103</originalsourceid><addsrcrecordid>eNptkU2LFDEURYMoTju6cy0BNy6sNi-pqlS5EGbar4YBRR1wIYSYvLLTViVtkhrpf2-aHgcVV4HkvEvePYQ8BLYEJrpnW2eXnAFfik7eIgtouKhA1vI2WTDGecUZ_3xC7qW0ZQzauunukhMuWN9KqBfkyzqFHDE7H5ynlwmp9pbmDdIPLn2nYaBrP4x6mnQOcU_Pw08c6UuXUCd8Ts_o-7CbR51d8NV5ubJ0FTYhZvoxz3Z_n9wZ9JjwwfV5Si5fv_q0eltdvHuzXp1dVKbuea6aWveDtExqw7Ux2g5CN70xokYO1qARjdSs6bXocIDGYsstCKZBcjNAKeGUvDjm7uavE5YJn6Me1S66Sce9Ctqpv1-826hv4UoJyTsmoAQ8uQ6I4ceMKavJJYPjqD2GOSmogTdNV6os6ON_0G2Yoy_rKRDQSiZFfwh8eqRMDClFHG4-A0wdtKmiTR20qaKt4I_-XOAG_u2pAO0RwFLjlcOoknHoDVoX0WRlg_t_8i-c36Z6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1316707391</pqid></control><display><type>article</type><title>Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Alhusayen, Raed O. ; Juurlink, David N. ; Mamdani, Muhammad M. ; Morrow, Richard L. ; Shear, Neil H. ; Dormuth, Colin R.</creator><creatorcontrib>Alhusayen, Raed O. ; Juurlink, David N. ; Mamdani, Muhammad M. ; Morrow, Richard L. ; Shear, Neil H. ; Dormuth, Colin R. ; for the Canadian Drug Safety and Effectiveness Research Network ; Canadian Drug Safety and Effectiveness Research Network</creatorcontrib><description>Limited evidence suggests that isotretinoin may be associated with inflammatory bowel disease (IBD). To explore this association, we conducted a retrospective population-based cohort study in British Columbia, Canada, among participants who were newly treated with isotretinoin or topical acne medications. The entire population of untreated provincial residents aged 12–29 years served as the reference group. During the 12-year study period, we identified 46,922 participants treated with isotretinoin, 184,824 treated with a topical acne medication, and 1,526,946 untreated individuals. Compared with untreated individuals, we observed no significant association between isotretinoin use and IBD (rate ratio (RR) 1.14; 95% confidence interval (CI) 0.92–1.41). As expected, we found no association with topical acne medications (RR 1.11; 95% CI 0.99–1.24). In prespecified secondary analyses, isotretinoin was associated with IBD among individuals aged 12–19 years (RR 1.39; 95% CI 1.03–1.87) and topical acne medications were associated with ulcerative colitis (RR 1.19; 95% CI 1.00–1.42). Our primary analyses found no association between isotretinoin and IBD. In prespecified secondary analyses, some evidence was found of associations with isotretinoin as well as topical acne medications, suggesting a possible association between IBD and acne itself. Additional research is needed to explore this possibility.</description><identifier>ISSN: 0022-202X</identifier><identifier>EISSN: 1523-1747</identifier><identifier>DOI: 10.1038/jid.2012.387</identifier><identifier>PMID: 23096714</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acne Vulgaris - drug therapy ; Acne Vulgaris - epidemiology ; Administration, Topical ; Adolescent ; Adult ; British Columbia - epidemiology ; Dermatologic Agents - administration & dosage ; Dermatologic Agents - adverse effects ; Female ; Follow-Up Studies ; Hospitalization - statistics & numerical data ; Humans ; Incidence ; Inflammatory bowel disease ; Inflammatory Bowel Diseases - epidemiology ; Isotretinoin - administration & dosage ; Isotretinoin - adverse effects ; Male ; Retrospective Studies ; Risk Factors ; Young Adult</subject><ispartof>Journal of investigative dermatology, 2013-04, Vol.133 (4), p.907-912</ispartof><rights>2013 The Society for Investigative Dermatology, Inc</rights><rights>Copyright Nature Publishing Group Apr 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-54a9f7d07ac2accadf3a59cc34e21dcec357a059a38ef15de62d130a172cf1103</citedby><cites>FETCH-LOGICAL-c492t-54a9f7d07ac2accadf3a59cc34e21dcec357a059a38ef15de62d130a172cf1103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1316707391?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,27922,27923,64383,64385,64387,72239</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23096714$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alhusayen, Raed O.</creatorcontrib><creatorcontrib>Juurlink, David N.</creatorcontrib><creatorcontrib>Mamdani, Muhammad M.</creatorcontrib><creatorcontrib>Morrow, Richard L.</creatorcontrib><creatorcontrib>Shear, Neil H.</creatorcontrib><creatorcontrib>Dormuth, Colin R.</creatorcontrib><creatorcontrib>for the Canadian Drug Safety and Effectiveness Research Network</creatorcontrib><creatorcontrib>Canadian Drug Safety and Effectiveness Research Network</creatorcontrib><title>Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study</title><title>Journal of investigative dermatology</title><addtitle>J Invest Dermatol</addtitle><description>Limited evidence suggests that isotretinoin may be associated with inflammatory bowel disease (IBD). To explore this association, we conducted a retrospective population-based cohort study in British Columbia, Canada, among participants who were newly treated with isotretinoin or topical acne medications. The entire population of untreated provincial residents aged 12–29 years served as the reference group. During the 12-year study period, we identified 46,922 participants treated with isotretinoin, 184,824 treated with a topical acne medication, and 1,526,946 untreated individuals. Compared with untreated individuals, we observed no significant association between isotretinoin use and IBD (rate ratio (RR) 1.14; 95% confidence interval (CI) 0.92–1.41). As expected, we found no association with topical acne medications (RR 1.11; 95% CI 0.99–1.24). In prespecified secondary analyses, isotretinoin was associated with IBD among individuals aged 12–19 years (RR 1.39; 95% CI 1.03–1.87) and topical acne medications were associated with ulcerative colitis (RR 1.19; 95% CI 1.00–1.42). Our primary analyses found no association between isotretinoin and IBD. In prespecified secondary analyses, some evidence was found of associations with isotretinoin as well as topical acne medications, suggesting a possible association between IBD and acne itself. Additional research is needed to explore this possibility.</description><subject>Acne Vulgaris - drug therapy</subject><subject>Acne Vulgaris - epidemiology</subject><subject>Administration, Topical</subject><subject>Adolescent</subject><subject>Adult</subject><subject>British Columbia - epidemiology</subject><subject>Dermatologic Agents - administration & dosage</subject><subject>Dermatologic Agents - adverse effects</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Incidence</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory Bowel Diseases - epidemiology</subject><subject>Isotretinoin - administration & dosage</subject><subject>Isotretinoin - adverse effects</subject><subject>Male</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Young Adult</subject><issn>0022-202X</issn><issn>1523-1747</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkU2LFDEURYMoTju6cy0BNy6sNi-pqlS5EGbar4YBRR1wIYSYvLLTViVtkhrpf2-aHgcVV4HkvEvePYQ8BLYEJrpnW2eXnAFfik7eIgtouKhA1vI2WTDGecUZ_3xC7qW0ZQzauunukhMuWN9KqBfkyzqFHDE7H5ynlwmp9pbmDdIPLn2nYaBrP4x6mnQOcU_Pw08c6UuXUCd8Ts_o-7CbR51d8NV5ubJ0FTYhZvoxz3Z_n9wZ9JjwwfV5Si5fv_q0eltdvHuzXp1dVKbuea6aWveDtExqw7Ux2g5CN70xokYO1qARjdSs6bXocIDGYsstCKZBcjNAKeGUvDjm7uavE5YJn6Me1S66Sce9Ctqpv1-826hv4UoJyTsmoAQ8uQ6I4ceMKavJJYPjqD2GOSmogTdNV6os6ON_0G2Yoy_rKRDQSiZFfwh8eqRMDClFHG4-A0wdtKmiTR20qaKt4I_-XOAG_u2pAO0RwFLjlcOoknHoDVoX0WRlg_t_8i-c36Z6</recordid><startdate>20130401</startdate><enddate>20130401</enddate><creator>Alhusayen, Raed O.</creator><creator>Juurlink, David N.</creator><creator>Mamdani, Muhammad M.</creator><creator>Morrow, Richard L.</creator><creator>Shear, Neil H.</creator><creator>Dormuth, Colin R.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7T2</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>20130401</creationdate><title>Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study</title><author>Alhusayen, Raed O. ; Juurlink, David N. ; Mamdani, Muhammad M. ; Morrow, Richard L. ; Shear, Neil H. ; Dormuth, Colin R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-54a9f7d07ac2accadf3a59cc34e21dcec357a059a38ef15de62d130a172cf1103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acne Vulgaris - drug therapy</topic><topic>Acne Vulgaris - epidemiology</topic><topic>Administration, Topical</topic><topic>Adolescent</topic><topic>Adult</topic><topic>British Columbia - epidemiology</topic><topic>Dermatologic Agents - administration & dosage</topic><topic>Dermatologic Agents - adverse effects</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Incidence</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory Bowel Diseases - epidemiology</topic><topic>Isotretinoin - administration & dosage</topic><topic>Isotretinoin - adverse effects</topic><topic>Male</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alhusayen, Raed O.</creatorcontrib><creatorcontrib>Juurlink, David N.</creatorcontrib><creatorcontrib>Mamdani, Muhammad M.</creatorcontrib><creatorcontrib>Morrow, Richard L.</creatorcontrib><creatorcontrib>Shear, Neil H.</creatorcontrib><creatorcontrib>Dormuth, Colin R.</creatorcontrib><creatorcontrib>for the Canadian Drug Safety and Effectiveness Research Network</creatorcontrib><creatorcontrib>Canadian Drug Safety and Effectiveness Research Network</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of investigative dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alhusayen, Raed O.</au><au>Juurlink, David N.</au><au>Mamdani, Muhammad M.</au><au>Morrow, Richard L.</au><au>Shear, Neil H.</au><au>Dormuth, Colin R.</au><aucorp>for the Canadian Drug Safety and Effectiveness Research Network</aucorp><aucorp>Canadian Drug Safety and Effectiveness Research Network</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study</atitle><jtitle>Journal of investigative dermatology</jtitle><addtitle>J Invest Dermatol</addtitle><date>2013-04-01</date><risdate>2013</risdate><volume>133</volume><issue>4</issue><spage>907</spage><epage>912</epage><pages>907-912</pages><issn>0022-202X</issn><eissn>1523-1747</eissn><abstract>Limited evidence suggests that isotretinoin may be associated with inflammatory bowel disease (IBD). To explore this association, we conducted a retrospective population-based cohort study in British Columbia, Canada, among participants who were newly treated with isotretinoin or topical acne medications. The entire population of untreated provincial residents aged 12–29 years served as the reference group. During the 12-year study period, we identified 46,922 participants treated with isotretinoin, 184,824 treated with a topical acne medication, and 1,526,946 untreated individuals. Compared with untreated individuals, we observed no significant association between isotretinoin use and IBD (rate ratio (RR) 1.14; 95% confidence interval (CI) 0.92–1.41). As expected, we found no association with topical acne medications (RR 1.11; 95% CI 0.99–1.24). In prespecified secondary analyses, isotretinoin was associated with IBD among individuals aged 12–19 years (RR 1.39; 95% CI 1.03–1.87) and topical acne medications were associated with ulcerative colitis (RR 1.19; 95% CI 1.00–1.42). Our primary analyses found no association between isotretinoin and IBD. In prespecified secondary analyses, some evidence was found of associations with isotretinoin as well as topical acne medications, suggesting a possible association between IBD and acne itself. Additional research is needed to explore this possibility.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23096714</pmid><doi>10.1038/jid.2012.387</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-202X |
| ispartof | Journal of investigative dermatology, 2013-04, Vol.133 (4), p.907-912 |
| issn | 0022-202X 1523-1747 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3728031 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | Acne Vulgaris - drug therapy Acne Vulgaris - epidemiology Administration, Topical Adolescent Adult British Columbia - epidemiology Dermatologic Agents - administration & dosage Dermatologic Agents - adverse effects Female Follow-Up Studies Hospitalization - statistics & numerical data Humans Incidence Inflammatory bowel disease Inflammatory Bowel Diseases - epidemiology Isotretinoin - administration & dosage Isotretinoin - adverse effects Male Retrospective Studies Risk Factors Young Adult |
| title | Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T01%3A42%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Isotretinoin%20Use%20and%20the%20Risk%20of%20Inflammatory%20Bowel%20Disease:%20A%20Population-Based%20Cohort%20Study&rft.jtitle=Journal%20of%20investigative%20dermatology&rft.au=Alhusayen,%20Raed%20O.&rft.aucorp=for%20the%20Canadian%20Drug%20Safety%20and%20Effectiveness%20Research%20Network&rft.date=2013-04-01&rft.volume=133&rft.issue=4&rft.spage=907&rft.epage=912&rft.pages=907-912&rft.issn=0022-202X&rft.eissn=1523-1747&rft_id=info:doi/10.1038/jid.2012.387&rft_dat=%3Cproquest_pubme%3E2916394071%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1316707391&rft_id=info:pmid/23096714&rft_els_id=S0022202X15361728&rfr_iscdi=true |